Interpace Biosciences

CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated

Interpace Commences $30M Rights Offering

Interpace Biosciences Q3 Revenues Rise 15 Percent

In Brief This Week: Quanterix, Cue Health, Hologic, CareDx, and More

Interpace Biosciences Q2 Revenues More Than Double

Interpace Biosciences Q1 Revenues Up 8 Percent

Interpace Biosciences to Review Strategic Alternatives

Interpace Biosciences Q4 Revenues More Than Double

In Brief This Week: Thermo Fisher, BioReference Laboratories, Hologic, Invitae, Danaher, and More

Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring

Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker

In Brief This Week: BioReference Laboratories, PerkinElmer, Fluidigm, Invitae, and More

Interpace Bio Q3 Revenues Rise 6 Percent

In Brief This Week: Enzo Biochem, 4D Path, Proscia, Quest Diagnostics, and More

Interpace Biosciences Q2 Revenues Decline 14 Percent

In Brief This Week: Myriad Genetics, Illumina, Quest, and More

Interpace Biosciences Q1 Revenues Rise 53 Percent

In Brief This Week: Meridian Bioscience, Clinical Genomics, InBios International, and More

Interpace Biosciences Q4 2019 Revenues Drop 29 Percent, Miss Analyst Predictions

In Brief This Week: Natera, Thermo Fisher Scientific, Fluidigm, and More